VRTX - Vertex Pharmaceuticals, Inc.
IEX Last Trade
407.63
-66.530 -16.321%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:01:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$474.16
-66.53
-14.03%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-10-28 | 2023-02-10 | 2023-05-02 | 2023-08-02 | 2023-11-07 | 2024-02-15 | 2024-05-07 | 2024-08-02 | |
| Total revenue | 2.334 B | 2.303 B | 2.375 B | 2.493 B | 2.484 B | 2.518 B | 2.691 B | 2.646 B | |
| Cost of revenue | 289.400 M | 283.300 M | 266.900 M | 308.600 M | 318.700 M | 368.000 M | 342.600 M | 371.900 M | |
| Gross profit | 2.045 B | 2.019 B | 2.108 B | 2.185 B | 2.165 B | 2.150 B | 2.348 B | 2.274 B | |
| -1.25% | 4.38% | 3.64% | -0.91% | -0.70% | 9.22% | -3.16% | |||
| Operating expenses | 891.800 M | 959.500 M | 983.700 M | 1.048 B | 1.074 B | 1.194 B | 1.132 B | 1.339 B | |
| Selling general and admin | 246.800 M | 267.400 M | 241.100 M | 262.600 M | 263.800 M | 369.100 M | 342.700 M | 372.200 M | |
| Research and development | 645.000 M | 692.100 M | 742.600 M | 785.700 M | 810.000 M | 824.600 M | 789.100 M | 966.600 M | |
| Total expenses | 1.181 B | 1.243 B | 1.251 B | 1.357 B | 1.393 B | 1.562 B | 1.474 B | 1.711 B | |
| 5.22% | 0.63% | 8.50% | 2.62% | 12.15% | -5.59% | 16.03% | |||
| Operating income | 1.153 B | 1.060 B | 1.124 B | 1.136 B | 1.091 B | 956.000 M | 1.216 B | 934.900 M | |
| Ebit | 1.153 B | 1.060 B | 1.124 B | 1.136 B | 1.091 B | 956.000 M | 1.216 B | 934.900 M | |
| Pretax income | 1.176 B | 1.077 B | 891.500 M | 1.162 B | 1.179 B | 1.148 B | 1.279 B | -3.391 B | |
| -8.47% | -17.21% | 30.29% | 1.52% | -2.68% | 11.46% | -365.12% | |||
| Income tax | 245.900 M | 257.900 M | 191.700 M | 245.800 M | 143.900 M | 178.800 M | 179.500 M | 202.400 M | |
| Net income basic | 930.500 M | 818.900 M | 699.800 M | 915.700 M | 1.035 B | 968.800 M | 1.100 B | -3.594 B | |
| -11.99% | -14.54% | 30.85% | 13.06% | -6.42% | 13.50% | -426.81% | |||
| Net income | 930.500 M | 818.900 M | 699.800 M | 915.700 M | 1.035 B | 968.800 M | 1.100 B | -3.594 B | |
| -11.99% | -14.54% | 30.85% | 13.06% | -6.42% | 13.50% | -426.81% |